# GSK’s RSV vaccine Arexvy accepted for review by Japan’s MHLW

- Link: https://www.directorstalkinterviews.com/gsks-rsv-vaccine-arexvy-accepted-for-review-by-japans-mhlw/4121135733
- Published: 2023-12-12T07:43:53+00:00
- Author: Amilia Stone

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**(
LON/NYSE: GSK) has announced that Japan’s Ministry of Health, Labour and Welfare(
MHLW) has accepted for review a regulatory application to extend the indication 
of GSK’s respiratory syncytial virus (RSV) vaccine (recombinant adjuvanted) for 
the prevention of RSV disease in adults aged 50-59 at increased risk.

·   Submission supported by positive results of a Phase III study showing immune
response and safety in adults aged 50-59

·   Adults aged 50 and above with certain underlying medical conditions are at increased
risk for RSV disease

·   GSK is the first company to seek regulatory approval to extend RSV vaccination
to this population

This regulatory submission follows Japan’s approval of GSK’s vaccine for the prevention
of RSV disease in adults from the age of 60 years, and the recent announcement of
the positive results (https://www.gsk.com/en-gb/media/press-releases/new-data-for-
arexvy-show-potential-to-help-protect-adults-aged-50-to-59/) of a phase III trial[
NCT05590403 https://clinicaltrials.gov/study/NCT05590403] evaluating the immune 
response and safety of GSK’s RSV vaccine in adults aged 50-59, including those at
increased risk for RSV lower respiratory tract disease (LRTD) due to certain underlying
medical conditions.

The burden of RSV disease in adults is likely to be underestimated due to lack of
awareness and standardised testing, as well as under-detection within surveillance
studies^([1]), but people with underlying medical conditions – such as chronic obstructive
pulmonary disease (COPD), asthma, chronic heart failure^([2]) and diabetes^([3])–
are at increased risk for RSV disease. RSV can exacerbate these conditions and lead
to pneumonia, hospitalisation, or death.^([4]) An international systematic review
of the prevalence of respiratory viruses in patients with acute exacerbations of
COPD, for example, showed that RSV was detected 1 in 10 cases.^([5])

GSK is the first company to seek regulatory approval to extend RSV vaccination to
help protect adults aged 50 to 59 at increased risk for RSV disease. Further announcements
on regulatory progress in the US and EU are expected in early 2024.

---

^([1]) Savic M, Penders Y, Shi T, Branche A, Pirçon J-Y. Respiratory syncytial virus
disease burden in adults aged 60 years and older in high-income countries: a systematic
literature review and meta-analysis, _Influenza Other Respir Viruses_ 2022 2023;
17:e13031

^([2]) Falsey, AR _et al_. Respiratory syncytial virus infection in elderly and 
high-risk adults, in _New Engl J Med_ 2005; 352:1749-59

^([3]) Richard Osei-Yeboah _et al_, Respiratory syncytial virus-associated hospitalisation
in adults with comorbidities in two European countries, PROMISE investigators, preprint,
August 2023

^([4]) Centers for Disease Control and Prevention (CDC), RSV in Older Adults and
Adults with Chronic Medical Conditions, 2023

^([5]) Zwaans WA _et al_., The relevance of respiratory viral infections in the 
exacerbations of chronic obstructive pulmonary disease-A systematic review, in _J
Clin Virol _2014;61:181-188

Share on:
